
Counter-Strike: Acend vs GenOne (BO3) - NODWIN Clutch Series Group Stage
Total Volume
$18K
24h Volume
$18K
Markets
12
Liquidity
$40K

Match Winner
$16K today
79%

Map 1 Winner
$2K today
100%

Map 2 Winner
$1K today
59%

Map Handicap: G1 (-1.5) vs Acend (+1.5)
$66 today
0%

Odd/Even Total Rounds
$20 today
100%

Odd/Even Total Kills
$5 today
52%

O/U 2.5 Games
$0 today
51%

Map Handicap: ACE (-1.5) vs GenOne (+1.5)
$0 today
51%

Odd/Even Total Kills
$0 today
51%

Odd/Even Total Rounds
$0 today
51%

Odd/Even Total Kills
$0 today
50%

Odd/Even Total Rounds
$0 today
51%
Ready to trade?
Put real money on your predictions.
About this event
This market refers to the Counter-Strike Round 3 match between Acend and GenOne in the NODWIN Clutch Series Group Stage, initially scheduled for April 18 at 7:00AM ET.
This market will resolve to "Acend" if Acend win the match against GenOne.
This market will resolve to "GenOne" if GenOne win the match against Acend.
If the match is canceled (not played at all), ends in a tie, or is delayed beyond 7 days from the scheduled date without a winner determined, this market will resolve to 50-50.
If the match begins but is not completed, and one team wins due to the opponent's forfeiture, disqualification, or walkover, this market will resolve to the team who wins.
If the match ends in a forfeit, disqualification, or walkover (team withdraws before the start and the other wins automatically), this market will resolve to 50-50.
The resolution source for this market will be official information from https://hltv.org. However, if https://hltv.org has not published final results within 2 hours after the event’s conclusion, a consensus of credible reporting may be used instead including video evidence.
In cases where a team’s listed name includes minor discrepancies from the resolution source, this market will resolve based on the underlying real-world match rather than exact name matching. Recognizable abbreviations, alternate or erroneous spellings, sponsor tags, affiliate or academy designations, regional identifiers, and minor formatting differences will be treated as referring to the same team, provided the intended team can be clearly and uniquely identified within the relevant competition. If a listed team name has no reasonable connection to any participating team, or if it matches or could reasonably refer to another team in the same competition such that the intended team cannot be unambiguously determined, this market will resolve 50-50.